Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FSI-189 |
Synonyms | |
Therapy Description |
FSI-189 is an antibody that targets SIRPA and inhibits the interaction between SIRPA and CD47 on tumor cells, which may lead to the activation of macrophages and phagocytic activity of tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FSI-189 | FSI189 | FSI-189 is an antibody that targets SIRPA and inhibits the interaction between SIRPA and CD47 on tumor cells, which may lead to the activation of macrophages and phagocytic activity of tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04502706 | Phase I | FSI-189 FSI-189 + Rituximab | Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Terminated | USA | 0 |